LeMaitre Vascular (NASDAQ:LMAT) Hits New 1-Year High Following Earnings Beat

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s stock price reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $112.65 and last traded at $105.6410, with a volume of 191905 shares trading hands. The stock had previously closed at $91.38.

The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The firm had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same period last year, the business posted $0.49 earnings per share. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s payout ratio is 31.87%.

Key Headlines Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and revenue growth — LMAT reported $0.68 EPS vs. $0.67 expected and revenue of $64.45M (vs. $62.98M est.), with revenue up 15.7% year-over-year; this is a primary catalyst for the stock move. Earnings Press Release
• Positive Sentiment: Raised guidance — Management boosted Q1 2026 EPS guidance to $0.640–$0.690 (vs. $0.62 consensus) and FY2026 EPS to $2.810–$3.010 (vs. $2.61 consensus), giving investors clearer upside to future earnings. Guidance Details
• Positive Sentiment: Dividend increase — LMAT declared a quarterly dividend of $0.25 (25% increase from $0.20), raising the yield to ~1.1% and signaling confidence in cash flow; ex-dividend March 12. (Company announcement)
• Positive Sentiment: Analyst bullishness — Roth MKM reaffirmed a “buy” and raised its price target to $117 (from $108), and Citizens JMP raised its target to $118 with a “market outperform” rating; both moves support upside expectations. Benzinga TickerReport
• Neutral Sentiment: Barrington Research raised its price target to $105 and kept an “outperform” rating — a positive signal on the rating but the target is below the current market price, making the impact mixed. Benzinga
• Neutral Sentiment: Relevant reads/transcript — The Q4 2025 earnings call transcript and analyst write-ups are available for investors who want detail on revenue drivers and margin outlook. Earnings Call Transcript
• Negative Sentiment: Wells Fargo raised its target to $94 but maintains an “equal weight” rating — the target sits materially below the current price, which could cap upside or encourage some selling from risk-averse holders. Benzinga

Analyst Ratings Changes

Several brokerages have weighed in on LMAT. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Citizens Jmp raised their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $106.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. grew its holdings in shares of LeMaitre Vascular by 3.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after purchasing an additional 118 shares during the last quarter. Illinois Municipal Retirement Fund boosted its position in LeMaitre Vascular by 1.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after buying an additional 123 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after buying an additional 139 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of LeMaitre Vascular by 1.2% during the fourth quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after buying an additional 147 shares in the last quarter. Finally, Johnson Investment Counsel Inc. lifted its stake in shares of LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 24.4%

The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $2.58 billion, a P/E ratio of 45.29, a PEG ratio of 2.03 and a beta of 0.72. The stock has a 50 day moving average price of $86.55 and a 200 day moving average price of $88.30.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.